Literature DB >> 30879638

Deleterious Variation in BRSK2 Associates with a Neurodevelopmental Disorder.

Susan M Hiatt1, Michelle L Thompson1, Jeremy W Prokop2, James M J Lawlor1, David E Gray1, E Martina Bebin3, Tuula Rinne4, Marlies Kempers4, Rolph Pfundt4, Bregje W van Bon4, Cyril Mignot5, Caroline Nava6, Christel Depienne7, Louisa Kalsner8, Anita Rauch9, Pascal Joset10, Ruxandra Bachmann-Gagescu10, Ingrid M Wentzensen11, Kirsty McWalter11, Gregory M Cooper12.   

Abstract

Developmental delay and intellectual disability (DD and ID) are heterogeneous phenotypes that arise in many rare monogenic disorders. Because of this rarity, developing cohorts with enough individuals to robustly identify disease-associated genes is challenging. Social-media platforms that facilitate data sharing among sequencing labs can help to address this challenge. Through one such tool, GeneMatcher, we identified nine DD- and/or ID-affected probands with a rare, heterozygous variant in the gene encoding the serine/threonine-protein kinase BRSK2. All probands have a speech delay, and most present with intellectual disability, motor delay, behavioral issues, and autism. Six of the nine variants are predicted to result in loss of function, and computational modeling predicts that the remaining three missense variants are damaging to BRSK2 structure and function. All nine variants are absent from large variant databases, and BRSK2 is, in general, relatively intolerant to protein-altering variation among humans. In all six probands for whom parents were available, the mutations were found to have arisen de novo. Five of these de novo variants were from cohorts with at least 400 sequenced probands; collectively, the cohorts span 3,429 probands, and the observed rate of de novo variation in these cohorts is significantly higher than the estimated background-mutation rate (p = 2.46 × 10-6). We also find that exome sequencing provides lower coverage and appears less sensitive to rare variation in BRSK2 than does genome sequencing; this fact most likely reduces BRSK2's visibility in many clinical and research sequencing efforts. Altogether, our results implicate damaging variation in BRSK2 as a source of neurodevelopmental disease.
Copyright © 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRSK2; Mendelian disease; clinical sequencing; de novo; developmental delay; exome; genome; intellectual disability

Mesh:

Substances:

Year:  2019        PMID: 30879638      PMCID: PMC6451696          DOI: 10.1016/j.ajhg.2019.02.002

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  33 in total

1.  Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia.

Authors:  Alissa M D'Gama; Ying Geng; Javier A Couto; Beth Martin; Evan A Boyle; Christopher M LaCoursiere; Amer Hossain; Nicole E Hatem; Brenda J Barry; David J Kwiatkowski; Harry V Vinters; A James Barkovich; Jay Shendure; Gary W Mathern; Christopher A Walsh; Annapurna Poduri
Journal:  Ann Neurol       Date:  2015-02-26       Impact factor: 10.422

2.  Mammalian SAD kinases are required for neuronal polarization.

Authors:  Masashi Kishi; Y Albert Pan; Justin Gage Crump; Joshua R Sanes
Journal:  Science       Date:  2005-02-11       Impact factor: 47.728

3.  LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1.

Authors:  Jose M Lizcano; Olga Göransson; Rachel Toth; Maria Deak; Nick A Morrice; Jérôme Boudeau; Simon A Hawley; Lina Udd; Tomi P Mäkelä; D Grahame Hardie; Dario R Alessi
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

4.  Genome Sequencing of Autism-Affected Families Reveals Disruption of Putative Noncoding Regulatory DNA.

Authors:  Tychele N Turner; Fereydoun Hormozdiari; Michael H Duyzend; Sarah A McClymont; Paul W Hook; Ivan Iossifov; Archana Raja; Carl Baker; Kendra Hoekzema; Holly A Stessman; Michael C Zody; Bradley J Nelson; John Huddleston; Richard Sandstrom; Joshua D Smith; David Hanna; James M Swanson; Elaine M Faustman; Michael J Bamshad; John Stamatoyannopoulos; Deborah A Nickerson; Andrew S McCallion; Robert Darnell; Evan E Eichler
Journal:  Am J Hum Genet       Date:  2015-12-31       Impact factor: 11.025

5.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Authors:  Andrew R Tee; Diane C Fingar; Brendan D Manning; David J Kwiatkowski; Lewis C Cantley; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

6.  Genic intolerance to functional variation and the interpretation of personal genomes.

Authors:  Slavé Petrovski; Quanli Wang; Erin L Heinzen; Andrew S Allen; David B Goldstein
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

Review 7.  Recurrent de novo mutations in neurodevelopmental disorders: properties and clinical implications.

Authors:  Amy B Wilfert; Arvis Sulovari; Tychele N Turner; Bradley P Coe; Evan E Eichler
Journal:  Genome Med       Date:  2017-11-27       Impact factor: 11.117

8.  Genomic diagnosis for children with intellectual disability and/or developmental delay.

Authors:  Kevin M Bowling; Michelle L Thompson; Michelle D Amaral; Candice R Finnila; Susan M Hiatt; Krysta L Engel; J Nicholas Cochran; Kyle B Brothers; Kelly M East; David E Gray; Whitley V Kelley; Neil E Lamb; Edward J Lose; Carla A Rich; Shirley Simmons; Jana S Whittle; Benjamin T Weaver; Amy S Nesmith; Richard M Myers; Gregory S Barsh; E Martina Bebin; Gregory M Cooper
Journal:  Genome Med       Date:  2017-05-30       Impact factor: 11.117

9.  Clinical sequencing: is WGS the better WES?

Authors:  Janine Meienberg; Rémy Bruggmann; Konrad Oexle; Gabor Matyas
Journal:  Hum Genet       Date:  2016-01-07       Impact factor: 4.132

10.  WIPI3 and WIPI4 β-propellers are scaffolds for LKB1-AMPK-TSC signalling circuits in the control of autophagy.

Authors:  Daniela Bakula; Amelie J Müller; Theresia Zuleger; Zsuzsanna Takacs; Mirita Franz-Wachtel; Ann-Katrin Thost; Daniel Brigger; Mario P Tschan; Tancred Frickey; Horst Robenek; Boris Macek; Tassula Proikas-Cezanne
Journal:  Nat Commun       Date:  2017-05-31       Impact factor: 14.919

View more
  3 in total

1.  Deleterious Variation in BR Serine/Threonine Kinase 2 Classified a Subtype of Autism.

Authors:  Jingxin Deng; Yi Wang; Meixin Hu; Jia Lin; Qiang Li; Chunxue Liu; Xiu Xu
Journal:  Front Mol Neurosci       Date:  2022-06-10       Impact factor: 6.261

2.  Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes.

Authors:  Pamela Feliciano; Xueya Zhou; Irina Astrovskaya; Tychele N Turner; Tianyun Wang; Leo Brueggeman; Rebecca Barnard; Alexander Hsieh; LeeAnne Green Snyder; Donna M Muzny; Aniko Sabo; Richard A Gibbs; Evan E Eichler; Brian J O'Roak; Jacob J Michaelson; Natalia Volfovsky; Yufeng Shen; Wendy K Chung
Journal:  NPJ Genom Med       Date:  2019-08-23       Impact factor: 8.617

3.  Genome-wide differentially methylated genes associated with posttraumatic stress disorder and longitudinal change in methylation in rape survivors.

Authors:  Jani Nöthling; Naeemah Abrahams; Sylvanus Toikumo; Matthew Suderman; Shibe Mhlongo; Carl Lombard; Soraya Seedat; Sian Megan Joanna Hemmings
Journal:  Transl Psychiatry       Date:  2021-11-19       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.